Hikal Share Price Gains Over 8%; Achieves Swissmedic GMP Certification for Bengaluru Facility

On October 30, 2026, Hikal Limited announced the receipt of a Certificate of GMP Compliance from Swissmedic for its active pharmaceutical ingredient manufacturing facility in Bengaluru, as per the exchange filings.  

This certification aligns with the EU-Switzerland Mutual Recognition Agreement. 

Swissmedic Certification for Bengaluru Facility 

On October 30, 2026, Hikal Limited disclosed that its Bengaluru facility has been awarded a Certificate of GMP Compliance by Swissmedic, the Swiss Agency for Therapeutic Products.  

This certification confirms the facility's adherence to stringent Good Manufacturing Practice standards, aligning with the Mutual Recognition Agreement between the European Union and Switzerland. 

Enhancing Global Regulatory Compliance 

The Swissmedic certification follows successful inspections by Brazil's ANVISA and Japan's PMDA, reinforcing the facility's standing with global regulatory bodies.  

These achievements position Hikal to serve a broader international customer base and diversify its pharmaceutical business geographically. 

Management's Perspective 

Mr. Sameer Hiremath, Chairman and Managing Director, highlighted that the certification endorses Hikal's quality systems. He stressed that quality, compliance, and manufacturing excellence are foundational for long-term partnerships and expanding global business reach. 

Corporate Background and Sustainability 

Established in 1988, Hikal operates as a life sciences partner, manufacturing active ingredients, intermediates, and biocides. The company has 5 manufacturing facilities across Maharashtra, Gujarat, and Bengaluru, supported by a Research and Technology centre in Pune.  

Hikal prioritises sustainability, holding a Responsible Care certification and an EcoVadis Gold Medal rating. 

Read More: Texmaco Rail Share Price in Focus; Gets Additional ₹412 Crore Railway Wagon Order! 

Hikal Share Price Performance 

As of October 30, 2026, at 10:04 AM, Hikal share price on NSE was trading at ₹221.07 up by 8.16% from the previous closing price. 

Conclusion 

Hikal Limited's Bengaluru facility has received Swissmedic GMP certification, confirming compliance with Good Manufacturing Practice standards. This certification, along with previous inspections by ANVISA and PMDA, enhances Hikal's global regulatory standing and expands its international market reach. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.